Cho Hyung Rae, Kim Seon Hwan, Kim Jin A, Min Jin Hye, Lee Yong Kyung
Department of Anesthesiology and Pain Medicine, Myongji Hospital, Goyang, Korea.
Korean J Pain. 2018 Apr;31(2):102-108. doi: 10.3344/kjp.2018.31.2.102. Epub 2018 Apr 2.
Nefopam is a non-opioid, non-steroidal analgesic drug with fewer adverse effects than narcotic analgesics and nonsteroidal anti-inflammatory drugs, and is widely used for postoperative pain control. Because nefopam sometimes causes side effects such as nausea, vomiting, somnolence, hyperhidrosis and injection-related pain, manufacturers are advised to infuse it slowly, over a duration of 15 minutes. Nevertheless, pain at the injection site is very common. Therefore, we investigated the effect of warmed carrier fluid on nefopam injection-induced pain.
A total of 48 patients were randomly selected and allocated to either a control or a warming group. Warming was performed by diluting 40 mg of nefopam in 100 ml of normal saline heated to 31-32℃ using two fluid warmers. The control group was administered 40 mg of nefopam dissolved in 100 ml of normal saline stored at room temperature (21-22℃) through the fluid warmers, but the fluid warmers were not activated.
The pain intensity was lower in the warming group than in the control group ( < 0.001). The pain severity and tolerance measurements also showed statistically significant differences between groups ( < 0.001). In the analysis of vital signs before and after the injection, the mean blood pressure after the injection differed significantly between the groups ( = 0.005), but the heart rate did not. The incidence of hypertension also showed a significant difference between groups ( = 0.017).
Use of warmed carrier fluid for nefopam injection decreased injection-induced pain compared to mildly cool carrier fluid.
奈福泮是一种非阿片类、非甾体类镇痛药,与麻醉性镇痛药和非甾体类抗炎药相比,不良反应较少,广泛用于术后疼痛控制。由于奈福泮有时会引起恶心、呕吐、嗜睡、多汗和注射相关疼痛等副作用,建议制造商缓慢输注,持续15分钟。然而,注射部位疼痛非常常见。因此,我们研究了温热载体液对奈福泮注射所致疼痛的影响。
共随机选取48例患者,分为对照组和温热组。通过使用两个液体加温器将40mg奈福泮稀释于100ml加热至31-32℃的生理盐水中进行加温。对照组通过液体加温器给予溶解于100ml室温(21-22℃)保存的生理盐水中的40mg奈福泮,但不启动液体加温器。
温热组的疼痛强度低于对照组(<0.001)。疼痛严重程度和耐受性测量结果也显示两组间存在统计学显著差异(<0.001)。在分析注射前后的生命体征时,两组注射后的平均血压存在显著差异(=0.005),但心率无差异。高血压发生率在两组间也存在显著差异(=0.017)。
与轻度凉爽的载体液相比,使用温热的载体液进行奈福泮注射可减轻注射所致疼痛。